Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)

16. juni 2026 oppdatert av: Wong Chun Ka, The University of Hong Kong

Wearable Assessment of Thoracic, Cardiac Health and Exercise Performance Trial Prospective (WATCH-XP)

Wearable health technology, particularly smartwatches, has revolutionized personal health monitoring by enabling continuous, non-invasive tracking of various physiological parameters. The potential applications of these devices in cardiology are extensive, but it is crucial to validate their accuracy against established medical-grade devices.

The Apple Watch Series 9 (Apple, USA) exemplifies the capabilities of modern smartwatches, offering a wide range of health tracking features. These include heart rate monitoring, detection of irregular heart rhythms suggestive of atrial fibrillation, electrocardiogram recording, blood oxygen level measurement, and comprehensive mobility metrics (including VO2 max, six-minute walk distance, walking speed, step length, double support time, and walking asymmetry). Many of these parameters are highly relevant for cardiovascular patients, potentially aiding in disease progression monitoring and adverse event prediction. However, there is a lack of comprehensive validation studies for these devices in specific cardiovascular disease populations.

This investigator-initiated, prospective observational study will consist of two phases: a training phase which involves 50 participants and a prospective validation phase which involves 20 participants. The study aims to validate smartwatch-based assessments using medical-grade devices and techniques. The study will focus on adult patients with congenital heart disease, pulmonary hypertension, heart failure, and coronary artery disease, as well as athletes undergoing cardiovascular assessment. By comparing smartwatch data with established clinical measurements, we seek to determine the reliability and potential clinical utility of these wearable devices in diverse cardiovascular contexts. Anonymized smartwatch data collected during the two phases will be published to a publicly registry to facilitate further research. This research will help bridge the gap between consumer-grade wearable technology and clinical practice in cardiology.

Studieoversikt

Detaljert beskrivelse

This study is investigator-initiated, prospective observational study and will consist of two phases: a training phase and a prospective validation phase.

Training Phase (First Phase) 50 participants will undergo comprehensive baseline assessments and continuous physiological monitoring with the smartwatch. Data collected during this phase will be anonymized and exported to a public open-source training model.

At Visit 1 of the first phase, Comprehensive demographic and clinical data will be collected from each participant, Clinical Management System (CMS), Electronic Patient Record (ePR), and Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. This will include age, sex, height, weight, body mass index, and detailed medical history focusing on cardiovascular conditions. Information about current medications and smoking status will also be recorded. Additionally, participants will undergo a baseline clinical examination, including blood pressure measurement, heart rate, and a 12-lead electrocardiogram.

VO2max Participants will undergo a conventional cardiopulmonary exercise test (CPX) to determine their maximal oxygen uptake (VO2max) at Visit 1. This test will be conducted in a controlled clinical setting under the supervision of cardiologists. Participants will exercise on a treadmill while their respiratory gas exchange is measured using a metabolic cart. The exercise intensity will be gradually increased until the participant reaches volitional exhaustion or predetermined safety criteria are met. The highest oxygen uptake value achieved during the test will be recorded as the VO2max. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment. This gold-standard measurement will serve as the reference for validating the smartwatch's continuous VO2max estimation.

6-Minute walk distance The 6-minute walk distance will be assessed in a hospital setting at Visit 2 of the first phase under the supervision of a research staff. Participants will be instructed to walk as far as possible in six minutes along a predetermined course, typically a straight hallway. The total distance walked will be measured and recorded. During the test, the research nurse will monitor the participant's heart rate, blood oxygen saturation, and perceived exertion at regular intervals. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment.

Oxygen saturation During the follow-up period of the first phase, participants will be provided with a medical-grade pulse oximeter for home use. They will be instructed to measure their oxygen saturation once daily throughout the one-week study period. Measurements should be taken at approximately the same time each day, preferably in the morning after waking and before any strenuous activity. Participants will record their oxygen saturation readings in a provided log. These daily measurements will serve as reference points for validating the continuous oxygen saturation data collected by the smartwatch.

Prospective Validation Phase (Second Phase) 20 participants will undergo similar assessments, with the primary aim of validating the smartwatch's measurements against medical-grade devices. Data collected during this phase also will be anonymized and exported to a public open-source training model.

At the Visit of the second phase, Comprehensive demographic and clinical data will be collected from each participant, Clinical Management System (CMS), Electronic Patient Record (ePR), and Clinical Data Analysis and Reporting System (CDARS) of the Hospital Authority in Hong Kong. This will include age, sex, height, weight, body mass index, and detailed medical history focusing on cardiovascular conditions. Information about current medications and smoking status will also be recorded. Additionally, participants will undergo a baseline clinical examination, including blood pressure measurement, heart rate, and a 12-lead electrocardiogram.

VO2max Participants will undergo a conventional cardiopulmonary exercise test (CPX) to determine their maximal oxygen uptake (VO2max) at Visit 1. This test will be conducted in a controlled clinical setting under the supervision of cardiologists. Participants will exercise on a treadmill while their respiratory gas exchange is measured using a metabolic cart. The exercise intensity will be gradually increased until the participant reaches volitional exhaustion or predetermined safety criteria are met. The highest oxygen uptake value achieved during the test will be recorded as the VO2max. Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment. This gold-standard measurement will serve as the reference for validating the smartwatch's continuous VO2max estimation.

Studietype

Observasjonsmessig

Registrering (Antatt)

20

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Chun Ka Wong
  • Telefonnummer: +852 2255 3111
  • E-post: wongeck@hku.hk

Studiesteder

      • Hong Kong, Hong Kong
        • Department of Medicine, Queen Mary Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients having adult congenital heart disease or pulmonary hypertension, heart failure or coronary artery disease, or are athletes undergoing cardiovascular assessment

Beskrivelse

Inclusion Criteria:

  • Age 20 to 70 years old
  • Ability to provide informed consent
  • History of the following cardiovascular conditions:
  • Adult congenital heart disease
  • Pulmonary hypertension
  • Heart failure
  • Coronary artery disease
  • Athletes undergoing cardiovascular assessment

Exclusion Criteria:

  • Contraindication for undergoing physical exertion including cardio-pulmonary exercise testing (CPX) and 6-minute walk test (6MWT)
  • Pregnancy
  • Known allergy to components of the investigational product

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
WatchXP
Participants will wear the investigational smartwatch (Apple Watch Series 9) concurrently for pre- and post-SaO2 and VO2max assessment during cardiopulmonary exercise test at the visit.
Participant will concurrently be wearing the investigational smartwatch for pre- and post-SaO2 and VO2max assessment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation between CPX VO2max and smartwatch parameters (virtual VO2 max, physical activity parameters)
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
VO2 max (ml/min/kg) concurrently measured with a medical-grade device and a smartwatch which has virutal VO2 max and physical activity parameters as assessed during treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Correlation between VO2 max (ml/min/kg) obtained using medical-grade device and smartwatch
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
VO2 max (ml/min/kg) obtained using medical-grade device and smartwatch during supervised treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment
Correlation between SaO2 (%) obtained using medical-grade device and smartwatch
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
SaO2 (%) obtained using medical-grade device and smartwatch during supervised treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment
SaO2 (%) measured by the smartwatch
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
SaO2 (%) measured by the smartwatch during supervised treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment
SaO2 (%) in participants with severe disease and participants with mild disease
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
SaO2 (%) in participants with severe versus mild disease during supervised treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment
Novel markers or patterns
Tidsramme: During treadmill exercise in the day of recruitment and concurrently baseline assessment
Novel markers or patterns indicative of disease severity or predictive of adverse events as assessed during supervised treadmill exercise
During treadmill exercise in the day of recruitment and concurrently baseline assessment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

16. juni 2026

Først innsendt som oppfylte QC-kriteriene

16. juni 2026

Først lagt ut (Faktiske)

23. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere